Generic Name: ceritinib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Zykadia is a kinase inhibitor approved for the treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC).
Zykadia interferes with anaplastic lymphoma kinase (ALK) and other receptor tyrosine kinases that play a role in cancer cell growth.
The ASCEND clinical trials showed that Zykadia improved response rates and delayed disease progression compared with chemotherapy in people with previously untreated metastatic ALK-positive NSCLC and in those who did not respond to the older ALK inhibitor Xalkori (crizotinib). Zykadia was approved in 2014.
Zykadia is taken tablet or capsule once daily with food.
Common adverse events include diarrhea, nausea, abdominal pain, vomiting and fatigue. More serious side effects may include severe gastrointestinal problems, liver toxicity, lung inflammation, heart rhythm abnormalities, pancreas inflammation and high blood glucose. Zykadia can cause fetal harm if used during pregnancy.
For More Info: https://www.us.zykadia.com/
Patient Assistance Program Info: https://www.us.zykadia.com/patient-support/financial-resources/
Last Reviewed: August 22, 2019